Braeburn is a pharmaceutical company dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid addiction. The company's mission is to advance a portfolio of next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of addiction faced by patients, healthcare professionals, payers and society.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

CURE PHARMACEUTICAL RECEIVES PATENT APPROVAL FOR ITS CUREFILM BLUE™ TECHNOLOGY

CURE Pharmaceutical Holding Corp. | November 17, 2021

news image

CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company focused on pharmaceutical and health & wellness products, announced today that it received an issue notification from the U.S. Patent Office (USPTO) stating that U.S. Patent No. 11,179,331 (the ’331 patent) is set to issue on November 23, 2021. The ’331 patent, entitled “Oral Soluble Film Containing Sildenafil Citrate,” covers the pr...

Read More

INDEX PHARMACEUTICALS TO PRESENT THE SUCCESSFUL RESULTS OF THE CONDUCT STUDY AT TWO LEADING MEDICAL CONFERENCES

Prnewswire | August 24, 2020

news image

We are very pleased that the abstract with the CONDUCT study results has been selected for oral presentation at both the UEGW and the ACG Annual Scientific Meeting", says Peter Zerhouni, CEO of InDex Pharmaceuticals. "These events are great opportunities for us to further reach the international scientific community with the successful results." UEGW is the largest scientific meeting for gastroenterologists in Europe and is this year held virtually October 11-13. The CONDUCT study...

Read More

Views and Analysis

INNOVENT AND IASO BIO PRESENT UPDATED DATA OF BCMA CAR-T CELL THERAPY (EQUECABTAGENE AUTOLEUCEL) AT EHA 2022

Innovent Biologics | June 13, 2022

news image

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and IASO Biotherapeutics a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today jointly announced that the updated data from phase 1/2 study of Equecabtagene Autoleucel (Inno...

Read More

Business Insights

ELLIPSES PHARMA AND SUNROCK BIOPHARMA ENTER INTO A LICENSING AGREEMENT FOR A FIRST-IN-CLASS BIFUNCTIONAL HER3:TRAIL FUSION PROTEIN

SunRock Biopharma S.L | May 26, 2022

news image

SunRock Biopharma S.L. a biopharmaceutical company that is developing a portfolio of innovative bispecific antibodies to treat incurable cancer, and Ellipses Pharma Limited a global drug development company focused on accelerating the development of new oncology treatments, announce that they have entered into an exclusive licensing agreement for SRB22, a fully human bifunctional HER3:TRAIL fusion protein, which going forward will be known as EP0017. Under the agreement, Ellipses ...

Read More
news image

Pharmacy Market

CURE PHARMACEUTICAL RECEIVES PATENT APPROVAL FOR ITS CUREFILM BLUE™ TECHNOLOGY

CURE Pharmaceutical Holding Corp. | November 17, 2021

CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company focused on pharmaceutical and health & wellness products, announced today that it received an issue notification from the U.S. Patent Office (USPTO) stating that U.S. Patent No. 11,179,331 (the ’331 patent) is set to issue on November 23, 2021. The ’331 patent, entitled “Oral Soluble Film Containing Sildenafil Citrate,” covers the pr...

Read More
news image

INDEX PHARMACEUTICALS TO PRESENT THE SUCCESSFUL RESULTS OF THE CONDUCT STUDY AT TWO LEADING MEDICAL CONFERENCES

Prnewswire | August 24, 2020

We are very pleased that the abstract with the CONDUCT study results has been selected for oral presentation at both the UEGW and the ACG Annual Scientific Meeting", says Peter Zerhouni, CEO of InDex Pharmaceuticals. "These events are great opportunities for us to further reach the international scientific community with the successful results." UEGW is the largest scientific meeting for gastroenterologists in Europe and is this year held virtually October 11-13. The CONDUCT study...

Read More
news image

Views and Analysis

INNOVENT AND IASO BIO PRESENT UPDATED DATA OF BCMA CAR-T CELL THERAPY (EQUECABTAGENE AUTOLEUCEL) AT EHA 2022

Innovent Biologics | June 13, 2022

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and IASO Biotherapeutics a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today jointly announced that the updated data from phase 1/2 study of Equecabtagene Autoleucel (Inno...

Read More
news image

Business Insights

ELLIPSES PHARMA AND SUNROCK BIOPHARMA ENTER INTO A LICENSING AGREEMENT FOR A FIRST-IN-CLASS BIFUNCTIONAL HER3:TRAIL FUSION PROTEIN

SunRock Biopharma S.L | May 26, 2022

SunRock Biopharma S.L. a biopharmaceutical company that is developing a portfolio of innovative bispecific antibodies to treat incurable cancer, and Ellipses Pharma Limited a global drug development company focused on accelerating the development of new oncology treatments, announce that they have entered into an exclusive licensing agreement for SRB22, a fully human bifunctional HER3:TRAIL fusion protein, which going forward will be known as EP0017. Under the agreement, Ellipses ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us